David Risinger
David Risinger is an analyst at Leerink Partners, focusing on the healthcare sector. He provided commentary on Johnson & Johnson's financial performance, noting the company's cautious approach in maintaining its earnings forecast amidst stock market volatility and the looming threat of tariffs. Risinger's analysis highlights the resilience of J&J in navigating a challenging economic landscape.
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United States:
David Risinger, an analyst with Leerink Partners, wrote in a note to clients that the tariffs should not affect many larger pharmaceutical companies because they have construction projects underway.
5
Slovenia:
David Risinger stated that Lilly could 'flood the world with orforglipron'.
8
Ireland:
David Risinger, a Leerink analyst, wrote that J&J’s decision not to slash its forecast is a welcome relief in the wake of recent stock market turmoil.
8